• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Jumps Over 300 Points; Zapp Electric Vehicles Group Shares Spike Higher

    6/20/24 2:35:07 PM ET
    $FEMY
    $MGOL
    $SONN
    $TPST
    Medical/Dental Instruments
    Health Care
    Apparel
    Consumer Discretionary
    Get the next $FEMY alert in real time by email

    U.S. stocks traded mixed toward the end of trading, with the Dow Jones index gaining more than 300 points on Thursday.

    The Dow traded up 0.87% to 39,171.26 while the NASDAQ fell 0.65% to 17,745.523. The S&P 500 also fell, dropping, 0.14% to 5,479.13.

    Check This Out: Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday

    Leading and Lagging Sectors

    Energy shares jumped by 2% on Thursday.

    In trading on Thursday, information technology shares fell by 1.1%.

    Top Headline

    The EIA said stocks of crude oil in the U.S. declined by 2.547 million barrels in the week ending June 14, compared to market estimates of a 2.800 million barrels decline.

    Equities Trading UP
                           

    • MGO Global, Inc. (NASDAQ:MGOL) shares shot up 66% to $0.7601 after the company said it expects the pending acquisition of Spetner Associates to close in the second half of 2024, projecting it to increase annualized revenue to approximately $28 million.
    • Shares of Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) got a boost, surging 129% to $3.09 after the company said it expects first customer deliveries of the i300 in the fourth quarter and anticipates selling over 5,000 units in the fiscal year ending Sept. 30, 2025.
    • Femasys Inc. (NASDAQ:FEMY) shares were also up, gaining 29% to $1.2302 after receiving CE Mark approval from the EU MDR for its FemaSeed, FemVue, FemCerv, and FemCath products.

    Equities Trading DOWN

    • Tempest Therapeutics, Inc. (NASDAQ:TPST) shares dropped 32% to $1.9480 after the company announced new data from the ongoing Phase 1b/2 clinical study on amezalpat2 (TPST-1120).
    • Shares of Trevena, Inc. (NASDAQ:TRVN) were down 30% to $0.2485. Trevena announced preclinical TRV045 data for long-term analgestic effect in prelinical model of neuropathic pain. Also, the company announced TRV045 results provided director for additional NIH-initiated studies in epilepsy prevention and treatment.
    • Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) was down, falling 31% to $1.07. Sonnet BioTherapeutics announced exercise of warrants for gross proceeds of $3.4 million.

    Also Check This Out: Top 4 Financial Stocks That Could Lead To Your Biggest Gains In Q2

    Commodities

    In commodity news, oil traded up 0.7% to $82.12 while gold traded up 1.1% at $2,372.10.

    Silver traded up 4.3% to $30.825 on Thursday, while copper rose 1.6% to $4.5620.

    Euro zone

    European shares closed higher today. The eurozone's STOXX 600 gained 0.93%, Germany's DAX rose 1.03% and France's CAC 40 gained 1.34%. Spain's IBEX 35 Index rose 0.94%, while London's FTSE 100 climbed 0.82%.

    The Bank of England held the Bank Rate at 5.25% during its recent meeting, as projected. Producer prices in Germany fell by 2.2% year-over-year in May compared to a 3.3% decline in the earlier month.

    Passenger car registrations in the European Union fell 3.0% year-over-year to a three-month low level of 911.7 thousand units in May.

    Asia Pacific Markets

    Asian markets closed mixed on Thursday, with Japan's Nikkei gaining 0.16%, Hong Kong's Hang Seng Index declining 0.52%, China's Shanghai Composite Index falling 0.42% and India's S&P BSE Sensex gaining 0.18%.

    The People’s Bank of China maintained key lending rates at the June fixing. Hong Kong's unemployment rate came in unchanged at 3% during the three months ending May. Singapore's unemployment rate increased to 2.1% in the first quarter of 2024 versus 2.0% in the prior period.

    Economics

    • The U.S. current account deficit rose by $15.8 billion to $237.6 billion during the first quarter, and versus market estimates of a $206.4 billion gap.
    • The Philadelphia Fed Manufacturing Index fell 3.2 points to a reading of 1.3 in June, missing market expectations of 5.
    • U.S. initial jobless claims fell by 5,000 to 238,000 in the second week of June, compared to market estimates of 235,000.
    • Housing starts in declined 5.5% to an annualized rate of 1.277 million in May, while building permits fell by 3.8% to an annual rate of 1.386 million.
    • The EIA said stocks of crude oil in the U.S. declined by 2.547 million barrels in the week ending June 14, compared to market estimates of a 2.800 million barrels decline.

    Now Read This: How To Earn $500 A Month From Smith & Wesson Brands Stock Ahead Of Q4 Earnings

    Get the next $FEMY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FEMY
    $MGOL
    $SONN
    $TPST

    CompanyDatePrice TargetRatingAnalyst
    Tempest Therapeutics Inc.
    $TPST
    1/22/2026$11.00Neutral → Buy
    H.C. Wainwright
    Femasys Inc.
    $FEMY
    11/20/2025$6.50Buy
    Laidlaw
    Tempest Therapeutics Inc.
    $TPST
    4/10/2025Sector Outperform → Sector Perform
    Scotiabank
    Tempest Therapeutics Inc.
    $TPST
    4/10/2025Buy → Neutral
    H.C. Wainwright
    Tempest Therapeutics Inc.
    $TPST
    3/14/2024$13.00Sector Outperform
    Scotiabank
    Tempest Therapeutics Inc.
    $TPST
    2/8/2024$15.00Buy
    Jefferies
    Sonnet BioTherapeutics Holdings Inc.
    $SONN
    2/9/2022$5.00 → $2.00Buy
    BTIG
    Sonnet BioTherapeutics Holdings Inc.
    $SONN
    12/20/2021$8.00 → $2.50Buy
    Chardan Capital
    More analyst ratings

    $FEMY
    $MGOL
    $SONN
    $TPST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets

    Tempest outlines a capital-efficient post-transaction strategy to advance a diversified portfolio of next-generation CAR-T and oncology assetsDevelopment approach prioritizes partner-funded and externally supported programs to generate clinical data before deploying significant internal capitalPipeline expansion includes TPST-4003, an in vivo dual-targeting CD19/BCMA CAR-T, with potential near-term milestones BRISBANE, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company with a diversified portfolio of cell therapy and small molecule product candidates, today outlined its post-transaction strategy to advan

    2/11/26 6:59:00 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets

    All-stock transaction brings Tempest a portfolio of next-generation CAR-T assets, including TPST-2003, a clinical-stage dual-targeting CD-19/BCMA CAR-T with strategic partner-funded BLA filing in China planned for 2027Operational runway extended to mid-2027, supporting multiple potential value-generating milestonesMatt Angel, Ph.D., joins Tempest as President and CEOPreviously announced transaction closed following stockholder approval of share issuance at the 2025 Annual Meeting on January 27, 2026 BRISBANE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company with a pipeline of advanced strategic therapeut

    2/4/26 4:47:13 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products

    ATLANTA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a new strategic distribution partnership with OR Consulting to support the commercial launch of its product portfolio in Switzerland. The agreement includes FemBloc Permanent Birth Control, FemaSeed Intratubal Insemination, and additional Femasys fertility and women's diagnostic health products. Together with the Company's recent market entry in Spain and the ongoing commercial launch in France, this partnership represents continued execution of Femasys' European

    2/3/26 9:15:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $FEMY
    $MGOL
    $SONN
    $TPST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Brady Stephen R bought $73,850 worth of shares (35,000 units at $2.11), increasing direct ownership by 308% to 46,376 units (SEC Form 4)

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    7/8/24 4:15:11 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Whiting Samuel bought $9,951 worth of shares (4,672 units at $2.13), increasing direct ownership by 95% to 9,573 units (SEC Form 4)

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    7/3/24 7:35:42 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corporate Controller Trojanowski Justin bought $16,200 worth of shares (7,500 units at $2.16), increasing direct ownership by 51% to 22,168 units (SEC Form 4)

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    7/2/24 4:15:14 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FEMY
    $MGOL
    $SONN
    $TPST
    SEC Filings

    View All

    Tempest Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)

    2/11/26 7:14:04 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Changes in Control of Registrant

    8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)

    2/6/26 4:12:27 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Tempest Therapeutics Inc.

    8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)

    1/28/26 4:05:33 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FEMY
    $MGOL
    $SONN
    $TPST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Tempest Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Tempest Therapeutics from Neutral to Buy and set a new price target of $11.00

    1/22/26 8:24:05 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Laidlaw initiated coverage on Femasys with a new price target

    Laidlaw initiated coverage of Femasys with a rating of Buy and set a new price target of $6.50

    11/20/25 8:06:38 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Tempest Therapeutics downgraded by Scotiabank

    Scotiabank downgraded Tempest Therapeutics from Sector Outperform to Sector Perform

    4/10/25 8:50:49 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FEMY
    $MGOL
    $SONN
    $TPST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Lee-Sepsick Kathy

    4 - FEMASYS INC (0001339005) (Issuer)

    2/20/26 5:37:51 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Financial Officer Elefant Dov

    4 - FEMASYS INC (0001339005) (Issuer)

    2/20/26 5:32:25 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Technology Officer Sipos Jeremy Alexander

    4 - FEMASYS INC (0001339005) (Issuer)

    2/17/26 5:47:34 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $FEMY
    $MGOL
    $SONN
    $TPST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Trevena Inc.

    SC 13G/A - TREVENA INC (0001429560) (Subject)

    11/14/24 4:43:11 PM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Trevena Inc.

    SC 13G - TREVENA INC (0001429560) (Subject)

    9/19/24 4:09:55 PM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Tempest Therapeutics Inc.

    SC 13D/A - Tempest Therapeutics, Inc. (0001544227) (Subject)

    8/12/24 8:59:00 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FEMY
    $MGOL
    $SONN
    $TPST
    Financials

    Live finance-specific insights

    View All

    Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

    BRISBANE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company with a pipeline of targeted and immune-mediated therapeutics to fight cancer, today announced the record date of January 30, 2026 (the "Record Date") for the distribution of warrants to purchase Tempest common stock ("Warrants") as a dividend (the "Warrant Dividends"), as contemplated by Tempest's previously announced Asset Purchase Agreement (the "Asset Purchase Agreement") with Erigen LLC and Factor Bioscience Inc. The distribution of the Warrant Dividends is expected to be Tuesday, February 3, 2026, but is subject to the prior satisfaction of c

    1/20/26 5:20:02 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

    -- Company delivers on mission to transform women's health with innovative solutions, including FemaSeed® for first-line infertility treatment and FemBloc® non-surgical permanent birth control (full system approval pending in Europe) -- ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the quarter ended March 31, 2025 and provides a corporate update. Corporate Highlights from 1Q 2025 to date Announced FemBloc permanent birth control delivery syste

    5/8/25 5:01:00 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

    -- Company expands commercial product offering with FemBloc® permanent birth control (delivery system) approval in Europe and signed partnerships for distribution in Spain -- ATLANTA, March 27, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the year ended December 31, 2024 and provides a corporate update. Corporate Highlights from 4Q 2024 to date Announced FemBloc® permanent birth control (delivery system) approval in Europe; FemBloc blended polymer component s

    3/27/25 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $FEMY
    $MGOL
    $SONN
    $TPST
    Leadership Updates

    Live Leadership Updates

    View All

    Femasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control Portfolios

    --Existing investors, including Femasys' largest shareholders, reaffirm confidence in Femasys' strategy for growth and impact in women's health-- ATLANTA, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today the closing of $8 million in financing. This funding will provide critical resources to accelerate commercialization efforts and strengthen the company's ability to address significant unmet needs in women's reproductive health. To underscore this momentum, Femasys' largest shareholder, Jorey Chernett also provided co

    9/2/25 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

    --New CCO to Lead U.S. Commercialization of Fertility Products, Including FemaSeed®, and Expand Strategic Global Partnerships Across Full Portfolio-- ATLANTA, June 17, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the appointment of Kelley Nicholas as Chief Commercial Officer (CCO). Ms. Nicholas will be responsible for leading the execution and optimization of Femasys' commercial strategy to drive revenue growth across its entire portfolio, with a particular focus on e

    6/17/25 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    After Major Oncology Conference, All Eyes Turn to Industry Innovation

    USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv

    6/12/25 9:00:00 AM ET
    $CAH
    $CTOR
    $CTXR
    Other Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations